The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Advances and perspectives of PARP inhibitors
Open accessAbstract
DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive genome instability and catastrophic DNA damage. Continuous DNA replication in cancer cells leads to higher demand of DNA repair components. Due to the oncogenic loss of some DNA repair effectors (e.g. BRCA) and incomplete DNA repair repertoire, some cancer cells are addicted to certain DNA repair pathways such as Poly (ADP-ribose) polymerase (PARP)-related single-strand break repair pathway. The interaction between BRCA and PARP is a form of synthetic lethal effect which means the simultaneously functional loss of two genes lead to cell death, while defect in any single gene has a slight effect on cell viability. Based on synthetic lethal theory, Poly (ADP-ribose) polymerase inhibitor (PARPi) was developed aiming to selectively target cancer cells harboring BRCA1/2 mutations. Recently, a growing body of evidence indicated that a broader population of patients could benefit from PARPi therapy far beyond those with germline BRCA1/2 mutated tumors. Numerous biomarkers including homologous recombination deficiency and high level of replication pressure also herald high sensitivity to PARPi treatment. Besides, a series of studies indicated that PARPi-involved combination therapy such as PARPi with additional chemotherapy therapy, immune checkpoint inhibitor, as well as targeted agent had a great advantage in overcoming PARPi resistance and enhancing PARPi efficacy. In this review, we summarized the advances of PARPi in clinical application. Besides, we highlighted multiple promising PARPi-based combination strategies in preclinical and clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 PARP and PARPis. a The structure schematic of PARP molecule. There are six main domains of PARP1 which include three zinc finger-related domains (DNA binding domains), one BRCA1 C-terminus domain (auto-modification domain), one tryptophan-/glycine-/arginine-rich domain (WGR domain), and one catalytic domain. The catalytic domain of PARP1 consists of two subdomains: one helical domain (HD) and one ADP-ribosyltransferase catalytic domain (ART). b Three-dimensional structure of PARP1 molecule. The above structures were presented by PyMOL Molecular Graphics System (PDB ID: 5XST [104]). c The chemistry structural formula of PARPis. d The function of PARP and synthetic lethal interaction between PARP and HR. Once DNA SSB emerges, PARP1 could recognizes and interacts with SSB by its zinc finger-related domains. After PARP1 binding to damaged DNA chains, the auto-inhibitory function of HD is abrogated and the catalytic function of ART is activated. This catalytic activity leads to the generation of PAR chains on a series of target proteins which promotes the recruitment of DNA repair effectors and chromatin remodeling. Then the auto-PARylation on PARP1 protein causes the dissociation of PARP1 from DNA chains and restores the auto-inhibitory status of PARP1. For HR deficient tumor cells, active SSB repair pathways is the vital prerequisites for cell survival. After PARPi treatment, NHEJ is used to repair PARPi-introduced DSB. However, NHEJ is a rapid as well as error-prone repair pathway by direct ligation. Due to the low-fidelity, NHEJ often produces plenty of chromosomal rearrangements and these unsustainable DNA damages are harmful to cell viability](/paper-figures/b8cba8b0fd6c416cb14979296998b864/advances-and-perspectives-of-parp-inhibitors-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As the core of SSB repair, PARP is the ideal target for drug development [222].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [222]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 3,013
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X. L., Fernandez‐Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,362
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Cited by
Sorted by citations
Items 101–118 of 118
Analysis of the role of CIZ1 in regulation of DNA replication
Tollitt, J. (2021) · Lancaster EPrints (Lancaster University) · doi:10.17635/lancaster/thesis/1291
A Comprehensive Tumor Molecular Profile Analysis in Clinical Practice: A Single Center’s ExperiencePreprint
Özdoğan, M., Papadopoulou, E., Τσούλος, Ν., Tsantikidi, A., Metaxa-Mariatou, V., Tsaousis, G. S., Kapeni, E., Bourkoula, E., Fotiou, D. F., Kapetsis, G., et al. (2020) · doi:10.21203/rs.3.rs-96233/v1
Characteristics and therapy of advanced cancer diseases
Taghizadeh, H. (2021)
Huang, C., & Tseng, L. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11407-5
Deoxyribonucleic Acid Damage Response Defects
Yin, M., Pomerantz, L. D., Vaca, R. A., Grivas, P. D., & Joshi, M. (2022) · Advances in Oncology · doi:10.1016/j.yao.2022.02.006
Vanderstichelen, G. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68013
Wang, Y., Li, K., Xu, W., & Gou, S. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4470917
Own Experience of Using Next-Generation Sequencing in the Diagnosis of BRCA-Associated Breast Cancer
Aristov, R. А., Дорофеев, А. В., Demidov, D. A., Анатольевич, Ц. Г., Magdalyanova, M. I., & Петкау, В. В. (2024) · Ural Medical Journal · doi:10.52420/umj.23.4.7
Future perspectives of retinoids in breast cancer prevention
Javeed, T., Mir, A. A., Masoodi, G., & Mir, M. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36516-4.00016-7
Sacituzumab Govitecan in the Treatment of Triple-Negative Breast Cancer: Present and Future
Li, C., Cheng, J., Chen, S., Zhao, S., Zhang, C., Sun, C., Wang, Y., & Liu, Q. (2025) · Current Breast Cancer Reports · doi:10.1007/s12609-025-00619-9
Additional file 1 of Comprehensive tumor molecular profile analysis in clinical practice
Özdoğan, M., Papadopoulou, E., Τσούλος, Ν., Tsantikidi, A., Mariatou, V.-M., Tsaousis, G., Kapeni, E., Bourkoula, E., Fotiou, D. F., Kapetsis, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14418204
Conceição, C. J. F., Moe, E., Ribeiro, P. A., & Raposo, M. (2026) · RSC Advances · doi:10.1039/d5ra02652k
Impact of low replication stress on the replication program of cancer and non-tumor cells
Courtot, L. (2020) · theses.fr (ABES) · doi:10.70675/74d8bf42zeebdz4323zb869zec66e6e29157
Kansara, Y., Desai, N., & Shah, P. (2026) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2026.2693870
A New Survey about Dual-Acting PARP/COX-2 Inhibitors as Cancer Chemopreventive Agents
Rabbani, M., Aliabadi, A., Bayat, L., Jafari, M., Bagheri, A. H., Shateri, S., Hakimimofrad, R., Bayanati, M., & Zarghi, A. (2026) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-169140
Zhao, C.-L., Wang, X.-P., Wei, K., Ge, Y.-J., & Sun, P.-L. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.07.004
BindingDB Entry 50015460: Discovery of Quinazoline-2,4(1
BindingDB (2023) · UC San Diego · doi:10.7270/q2kk9grt
BindingDB Entry 50020475: Discovery of Quinazoline-2,4(1
BindingDB (2024) · UC San Diego · doi:10.7270/q2d79gv5
Metadata
- Authors
- Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S.
- Affiliations
- Tongji Hospital (CN)
- Zhengzhou University (CN)
- Corresponding author
- Wu, Kongming
- Luo, Suxia
- Venue
- Experimental Hematology & Oncology
- Published
- 2019-11-11
- Volume
- 8
- Issue
- 1
- Pages
- 29-29
- ISSN
- 2162-3619 (ISSN-L)
- PMC
- PMC6849303
- OpenAlex
- W2987653633
- Cited by
- 117
- References
- 104
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 7 · 2023: 18 · 2022: 19 · 2021: 33 · 2020: 22
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Experimental Hematology and Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81874120, 81572608, 81672984)
- Wuhan Municipal Science and Technology Bureau (2017060201010170)
- Natural Science Foundation of Henan Province (162300410266)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- PARP inhibitors, DNA repair deficiency, synthetic lethality, BRCA mutations, homologous recombination deficiency, single-strand break repair, genomic instability, PARP inhibitor resistance, combination therapy, immune checkpoint inhibitors, combination chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
